肌肉生长抑制素与终末期肝病肌肉减少症的关系

Association between myostatin and sarcopenia in end-stage liver disease

终末期肝病(ESLD)患者普遍存在肌肉减少症(MD)和脂肪减少为代表的恶病质状态,既往认为这种状态与营养不良相关。近年来发现肌肉生长抑制素(MSTN)与ESLD病情进展相关。研究发现MSTN通过影响糖、脂肪、蛋白质代谢及肌细胞数量等导致MD、恶病质状态;MSTN可以作为HCC的筛查指标、病情进展观察指标。通过MSTN途径干预可能是控制ESLD患者MD、恶病质的有效方法,是预测肝硬化向HCC发展的有效指标。

Patients with end-stage liver disease(ESLD)are often accompanied by various complications such as sarcopenia and cachexia including lipopenia,and it was believed in the past that such status was associated with malnutrition,while recent studies have shown that myostatin(MSTN)is associated with the progression of ESLD.MSTN can lead to sarcopenia and cachexia by affecting the metabolism of glucose,fat,and protein and the number of myocytes,and it can be used as a screening indicator for hepatocellular carcinoma(HCC)and an indicator for disease progression.Intervention via the MSTN pathway might be an effective method for controlling sarcopenia and cachexia in patients with ESLD,and MSTN may be an effective indicator for predicting the progression of liver cirrhosis to HCC.